$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
肺癌患者服用奥希替尼,在饮食上应注意什么?
2025-10-19 11:44:20
Check Details
易瑞沙在服用后的药物吸收程度怎么样?
2025-10-19 11:44:20
Check Details
高脂饮食会增加肺癌发病风险
2025-10-19 11:44:20
Check Details
生活中如何预防肺癌?
2025-10-19 11:44:20
Check Details
易瑞沙直接作用在HER3致癌位点上
2025-10-19 11:44:20
Check Details
EGFR基因突变者一线治疗厄洛替尼
2025-10-19 11:44:20
Check Details
摄取较少维A,肺癌的比率明显偏高
2025-10-19 11:44:20
Check Details
服用阿法替尼的注意事项
2025-10-19 11:44:20
Check Details
卡博替尼+厄洛替尼治疗EGFR晚期NSCLC患者
2025-10-19 11:44:20
Check Details
FDA批准色瑞替尼用于转移性非小细胞肺癌的治疗
2025-10-19 11:44:20
Check Details
克唑替尼首个间变性淋巴瘤激酶(ALK)肺癌靶向药物
2025-10-19 11:44:20
Check Details
哪些患者不适合服用色瑞替尼?
2025-10-19 11:44:20
Check Details
1
2
...
2967
2968
2969
2970
2971
2972
2973
...
4160
4161
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Mirdametinib Mechanism and Clinical Guide: MEK Inhibitor for NF1 Plexiform Neurofibromas
2
Acalabrutinib Dosing and Efficacy Guide: Administration, Response Evaluation, and Safety
3
Osimertinib Treatment and Dosing Guide: Efficacy, Administration, and Precautions
4
Ceritinib Dosing Guide: 450mg Once Daily with Food – Key Administration Points
5
Ruxolitinib Drug Safety Guide: Drug Interactions, Hepatic/Renal Function, and Infection Risk Management
6
Belzutifan (WELIREG) Treatment Guide: Duration, Onset of Action, and Monitoring Protocol
7
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
8
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
9
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
10
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
11
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
12
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide